Atreya
A HealthTech company using Ayurvedic pulse diagnosis to build non-invasive solutions for detecting and preventing diabetes.
About
Atreya draws on Ayurvedic knowledge to build non-invasive solutions for detecting and preventing diabetes. It reports being the first to win patents for non-invasive diabetes detection technology in several regions worldwide.
Its product applies Nadi Pariksha, the practice of reading the pulse, to assess overall health, disease patterns such as diabetes and hypertension, and mental well-being such as stress and anxiety, giving a predictive prognosis.
Why We Invested
We invested in Atreya for several reasons together. It offers a non-invasive way to detect diabetes, built on patented technology that combines the Ayurvedic practice of Nadi Pariksha with modern product development, and the same approach extends to hypertension and mental well-being. Both founders are IIT Bombay alumni, bringing deep knowledge of pulse-based diagnostics and over a decade of product development.
The company also addresses a large market. The global diabetes diagnostics market is valued at USD 36.6 billion, growing at a CAGR of 9.1%, and is expected to pass USD 70 billion by 2032. The Indian Ayurveda market is expected to reach USD 26 billion by 2032, growing at a CAGR of 15%.
Team
Founder & CEO
IIT Bombay alumnus with a deep understanding of pulse-based diagnostic methods, developed during his time there.
Co-Founder & CRO
IIT Bombay alumnus with over a decade of product development experience.